Related Experiment Video
Updated: Jun 14, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
GM-CSF-armed, replication-competent viruses for cancer
1Billings Clinic, Department of Hematology and Oncology, United States. jburke@billingsclinic.org
Abstract:
Monoclonal antibody therapy for cancer has significantly altered the natural history of several common cancers. This success was attained only after many years of failure to understand the technical limitations of antibody therapy. In order to further exploit the immune system, tumor vaccine strategies are an active research focus. Virus based immune agents including GM-CSF armed vectors are among these early efforts. Herpes, adenovirus, and vaccinia based vectors encoding GM-CSF have reported intriguing early clinical trial results that are reviewed here.
Insights
Monoclonal antibody therapy has advanced cancer treatment. New research explores virus-based tumor vaccines, like GM-CSF armed vectors, showing promising early clinical results for cancer immunotherapy.
Area of Science:
- Oncology
- Immunotherapy
- Virology
Background:
- Monoclonal antibody therapy has revolutionized cancer treatment after initial challenges.
- Understanding technical limitations paved the way for current successes.
- Exploiting the immune system remains a key strategy in cancer research.
Purpose of the Study:
- To review current research on tumor vaccine strategies.
- To highlight the role of virus-based immune agents in cancer therapy.
- To discuss early clinical trial results of GM-CSF armed vectors.
Main Methods:
- Review of existing literature on virus-based immune agents.
- Focus on herpes, adenovirus, and vaccinia vectors.
- Analysis of early clinical trial data for GM-CSF encoding vectors.
Main Results:
- Intriguing early clinical trial results reported for virus-based immune agents.
- GM-CSF armed vectors show potential in cancer vaccine strategies.
- Herpes, adenovirus, and vaccinia vectors are being investigated.
Conclusions:
- Virus-based immune agents, including GM-CSF armed vectors, represent a promising area of cancer immunotherapy research.
- Early clinical data suggest potential efficacy, warranting further investigation.
- These strategies aim to further exploit the immune system for cancer treatment.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Cytomegalovirus Disease
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mechanisms of Retrovirus-induced Cancers

